Response
- PMID: 24394846
- PMCID: PMC7130316
- DOI: 10.1378/chest.13-2620
Response
Comment on
-
High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.Chest. 2013 Jul;144(1):106-118. doi: 10.1378/chest.12-2357. Chest. 2013. PMID: 23348146 Clinical Trial.
-
N-Acetylcysteine Protection in COPD: An Alternative Mechanism of Action.Chest. 2014 Jan;145(1):193-4. doi: 10.1378/chest.13-2029. Chest. 2014. PMID: 24394845 No abstract available.
References
-
- Tse HN, Raiteri L, Wong KY. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013;144(1):106–118. - PubMed
-
- Radomska-Leśniewska DM, Sadowska AM, Van Overveld FJ, Demkow U, Zieliński J, De Backer WA. Influence of N-acetylcysteine on ICAM-1 expression and IL-8 release from endothelial and epithelial cells. J Physiol Pharmacol. 2006;57(suppl 4):325–334. - PubMed
-
- Linden M, Wieslander E, Eklund A, Larsson K, Brattsand R. Effects of oral N-acetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers. Eur Respir J. 1988;1(7):645–650. - PubMed
-
- Eklund A, Eriksson O, Håkansson L. Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur Respir J. 1988;1(9):832–838. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
